Clinical Trials Logo

Endometrial Adenocarcinoma clinical trials

View clinical trials related to Endometrial Adenocarcinoma.

Filter by:

NCT ID: NCT06066216 Not yet recruiting - Endometrial Cancer Clinical Trials

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with chemotherapy in patients with recurrent or advanced endometrial cancer. The primary objective is to evaluate objective response rate of cadonilimab plus chemotherapy.

NCT ID: NCT05824481 Not yet recruiting - Endometrial Cancer Clinical Trials

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with lenvatinib in patients with advanced endometrial cancer. The primary objective is to evaluate objective response rate of cadonilimab plus lenvatinib.

NCT ID: NCT05655260 Recruiting - Clinical trials for Endometrial Adenocarcinoma

PErsonalized TReatment for Endometrial Carcinoma

PETREC
Start date: February 8, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. Specifically, the invesigators want to compare: - Chemotherapy vs. chemoradiotherapy in p53 abn subtype and nonendometrioid carcinomas. - Vaginal brachytherapy vs. whole pelvic radiotherapy in the MMR-D molecular subgroup. - Vaginal brachytherapy vs. whole pelvic radiotherapy in the NSMP molecular subgroup.

NCT ID: NCT05548296 Recruiting - Clinical trials for Urothelial Carcinoma

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Start date: August 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status.

NCT ID: NCT05498597 Recruiting - Ovarian Cancer Clinical Trials

AMT-151 in Patients With Selected Advanced Solid Tumours

Start date: January 25, 2023
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.

NCT ID: NCT05112601 Recruiting - Clinical trials for Endometrial Carcinoma

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Start date: June 2, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.

NCT ID: NCT05001282 Recruiting - Ovarian Cancer Clinical Trials

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Start date: September 13, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study, ELU- FRα-1, is focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available. ELU001 is a new chemical entity described as a C'Dot drug conjugate (CDC), consisting of payloads (exatecans) and targeting moieties (folic acid analogs) covalently bound by linkers to the C'Dot particle carrier. ELU001 will be the first drug-conjugate of its kind to be introduced into the clinic, a first in class, and a novel molecular entity.

NCT ID: NCT04972682 Active, not recruiting - Endometrial Cancer Clinical Trials

[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer

SENTRY
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

While total hysterectomy without lymph node staging is standard for low- and intermediate-risk endometrial cancer, certain histopathologic factors can necessitate additional interventions. Our study assesses the influence of sentinel lymph node (SLN) biopsy on postoperative decision-making.

NCT ID: NCT04873206 Completed - Clinical trials for Endometrial Adenocarcinoma

Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies

Start date: January 1, 2020
Phase:
Study type: Observational

endometrial hyperplasia may progress to endometrial adenocarcinoma. the exact possibility of such progression is not determined. there a need to detect biological markers that can help in detecting high risk cases of patients with endometrial hyperplasia that may progress to endometrial adenocarcinoma. PTEN is a tumor suppressor gene that inhibit cell migration, proliferation and may induce apoptosis in damaged cells. variable expression of PTEN in functional, hyperplastic and neoplastic endometrial tissues may be of great help in detecting cases of hyperplasia that may progress to endometrial adenocarcinoma.

NCT ID: NCT04106414 Active, not recruiting - Clinical trials for Endometrial Adenocarcinoma

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Start date: September 24, 2019
Phase: Phase 2
Study type: Interventional

This study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects.